In this article, we will look at the 10 High Growth Stocks Insiders Are Buying.
Insider buying tends to get attention because it signals that company executives are putting personal capital behind their own businesses. When insider purchases line up with strong earnings growth, improving revisions, or a better sector backdrop, the signal becomes harder to dismiss.
Tweedy, Browne describes the appeal as an “insider’s edge,” noting that insider buying may suggest executives “believe the stock price will increase,” while also warning it is “not a ‘sure thing’ in investing.” Insider buying is a clue, not proof. BlackRock adds that “Earnings strength is broadening” and points to a “new trend of upward revisions,” with “non-Mag 7 earnings power may be underappreciated.” In summary, growth opportunities may be spreading beyond the largest market leaders. Fidelity says “Tech is still king” and remains “ground zero for earnings growth,” adding that “technology remains difficult to replace” for investors looking for durable expansion.
Against this backdrop, high-growth stocks with insider buying offer an interesting mix of internal confidence and external earnings momentum. The key is finding cases where insiders are buying into improving fundamentals, not just trying to signal support after weakness. With that in mind, let’s take a look at the 10 High-Growth Stocks Insiders Are Buying.
Our Methodology
We used the Finviz screener to identify stocks with a significant increase in insider ownership over the last six months. We then filtered for stocks that have exhibited compounded annual earnings growth of at least 20% over the past three years and thereafter limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Sonida Senior Living, Inc. (NYSE:SNDA)
On June 29, 2026, RBC Capital analyst Ben Hendrix raised the firm’s price target on Sonida Senior Living, Inc. (NYSE:SNDA) to $48 from $45 and kept an Outperform rating on the shares. Hendrix said the updated price target better reflects the company’s momentum as it enters its compounding growth phase.
Earlier in June, Sonida Senior Living announced that Anton Nikodemus was appointed to the newly created role of Chief Operating Officer, effective June 15, 2026. Nikodemus brings 30 years of executive-level hospitality and operations leadership to Sonida and will oversee end-to-end operational performance across the portfolio.
Towards the end of May, Morgan Stanley raised the firm’s price target on Sonida Senior Living to $38 from $31 and kept an Equal Weight rating on the shares. Morgan Stanley updated its estimates as the CHP merger impact comes into focus, but took “a wait and see approach on execution.”
Sonida Senior Living, Inc. (NYSE:SNDA) owns and operates senior housing communities in the United States.
9. Zura Bio Limited (NASDAQ:ZURA)
On July 8, 2026, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating. The firm sees potential for the dual mechanism of action of tibulizumab to drive “differentiated efficacy” in two ongoing Phase 2 studies in hidradenitis suppurativa and systemic sclerosis.
On June 29, Zura Bio announced several tibulizumab program updates. The company completed enrollment of the Phase 2 TibuSHIELD trial of tibulizumab in adults with HS, exceeding the target enrollment with 247 participants enrolled. Zura also remained on track to complete enrollment of the Phase 2 TibuSURE trial of tibulizumab in adults with early diffuse cutaneous SSc in early July, with the trial already exceeding its target enrollment of 80 participants.
Topline data from TibuSHIELD are expected in the fourth quarter of 2026, while topline data from TibuSURE are expected in H1 2027. Zura also plans to initiate a Phase 2 study in a third immune-mediated indication by year-end 2026 and announce the new indication before study initiation. Also on June 29, Zura said it had cash and cash equivalents of $225.6M as of March 31, 2026, and continues to expect its existing cash to fund planned operations through at least the end of 2028.
Zura Bio Limited (NASDAQ:ZURA) develops medicines for autoimmune and inflammatory disorders in the United States.
8. Eightco Holdings Inc. (NASDAQ:ORBS)
On July 9, 2026, Eightco Holdings Inc. (NASDAQ:ORBS) provided an update on its total holdings, highlighting its positions across digital assets and strategic investments in private technology companies. As of July 8, 2026, the company’s holdings included a $90M investment in OpenAI, an $18M funded investment in Beast Industries, a $1M investment in Mythical Games, 283,452,700 Worldcoin at $0.39 per WLD, 16,278 Ethereum, and approximately $149M in total cash and stablecoins, for total holdings of approximately $397M. Board member Thomas “Tom” Lee said AI capabilities and innovations continue to “astound markets.” Lee also cited OpenAI’s upcoming release of GPT-5.6 and its acquisition of Northslope as signs that the next phase of AI includes both more capable models and enterprise adoption at scale.
On July 2, Eightco said its holdings as of July 1 totaled approximately $386M, including a $90M investment indirectly, through SPVs in OpenAI, an $18M funded investment in Beast Industries, a $1M investment in Mythical Games, 283,452,700 Worldcoin at 36c per Coinbase, 16,278 Ethereum, and approximately $149M in total cash and stablecoins. On June 25, the company said its holdings as of June 24 totaled approximately $436M, with the same investments and 283,452,700 Worldcoin at 54c per Coinbase.
Eightco Holdings Inc. (NASDAQ:ORBS) provides inventory management solutions and funding solutions for e-commerce businesses in North America and Europe.
7. Outlook Therapeutics, Inc. (NASDAQ:OTLK)
On June 16, 2026, Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced that the U.S. Food and Drug Administration acknowledged receipt of the resubmission of the Biologics License Application for ONS-5010/LYTENAVA for the treatment of neovascular age-related macular degeneration, or wet AMD. The company was informed that the resubmission is a Class 1 review, with a PDUFA target action date of July 29, 2026.
CEO Bob Jahr said the FDA accepted the resubmitted BLA to review the labeling as part of the “final step toward potential approval.” Outlook said ONS-5010/LYTENAVA would be the first and only FDA-approved ophthalmic formulation of bevacizumab supported by standardized manufacturing, FDA-approved labeling, and robust pharmacovigilance if approved. The company has initiated pre-launch activities in anticipation of the pending BLA approval.
Earlier in June, Outlook Therapeutics announced the resubmission of its BLA to the FDA for ONS-5010/LYTENAVA for the treatment of nAMD. The company said it successfully appealed the December 2025 Complete Response Letter related to the ONS-5010 BLA. The FDA Office of New Drugs concluded that substantial evidence of effectiveness has been established for LYTENAVA for the treatment of nAMD, and that additional trials are not required. Outlook said the formal decision indicated a Class 1 resubmission, with a PDUFA date and decision expected within 60 days of FDA receipt.
Outlook Therapeutics, Inc. (NASDAQ:OTLK) focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
6. Lamb Weston Holdings, Inc. (NYSE:LW)
On July 9, 2026, JPMorgan analyst Thomas Palmer raised the firm’s price target on Lamb Weston Holdings, Inc. (NYSE:LW) to $48 from $43 and kept a Neutral rating on the shares.
On July 8, Wells Fargo raised the firm’s price target on Lamb Weston to $54 from $46 and kept an Overweight rating on the shares. Wells Fargo said its target price-to-earnings multiple remains at a discount to historical trading ranges due to recent supply and demand pressure and limited near-term visibility. While International and mixed headwinds remain an overhang, the firm said it remains encouraged by the North America turnaround, where over 85% of segment profit resides.
Last month, Lamb Weston announced plans to close its production facility in Broekhuizenvorst, the Netherlands, to align its global supply chain footprint with evolving market conditions and broader executional excellence efforts. Chief Supply Chain Officer Sylvia Wilks said the actions are part of the company’s commitment to the “long-term resilience and competitiveness” of its global supply chain network. The company will now initiate a formal consultation process with the Works Council in accordance with Dutch regulations.
Lamb Weston Holdings, Inc. (NYSE:LW) produces, distributes, and markets frozen potato products in the United States, Canada, Mexico, and internationally.
5. Alpha Cognition Inc. Common Stock (NASDAQ:ACOG)
On July 10, 2026, Raymond James analyst Ryan Deschner initiated coverage of Alpha Cognition Inc. (NASDAQ:ACOG) with an Outperform rating and $20 price target. Deschner noted that Alpha Cognition markets Zunveyl, a prodrug of FDA-approved galantamine indicated for the treatment of mild-to-moderate dementia in patients with Alzheimer’s disease.
Deschner said Zunveyl is designed to address a large unmet need in Alzheimer’s disease, including gastrointestinal tolerability and other adverse events that are a primary source of discontinuation for the most commonly prescribed class of Alzheimer’s disease drugs, acetylcholinesterase inhibitors.
On June 24, Alpha Cognition Inc. (NASDAQ:ACOG) announced changes to its Board of Directors. Robert Wills was elected Chairman of the Board, succeeding Len Mertz, who retired from the Board.
On June 16, Alpha Cognition announced enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. The study is expected to enroll approximately 150 patients across multiple clinical sites and monitor adverse events, treatment persistence, and discontinuation rates.
Alpha Cognition Inc. (NASDAQ:ACOG) develops treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
4. Neuronetics, Inc. (NASDAQ:STIM)
On July 6, 2026, Neuronetics, Inc. (NASDAQ:STIM) announced that management will participate at B. Riley Securities’ Mind, Muscle & Vision Summit, an invitation-only institutional investor event being held in person at the InterContinental Boston. Neuronetics will participate in a panel discussion titled “Commercializing the Next Wave of Novel Neuropsychiatric Drugs” alongside Compass Pathways on Thursday, July 16, 2026. Management will also be available for one-on-one meetings with institutional investors throughout the day.
On June 2, Neuronetics announced its participation as a Silver Sponsor at the 2026 Clinical TMS Society Annual Meeting. The company said real-world data from its proprietary TrakStar database will be featured in an oral presentation and multiple scientific posters focused on transcranial magnetic stimulation for mental health conditions. Chief Technology Officer Cory Anderson said the expansion of real-world evidence is “critical” to advancing the understanding of TMS and its role in clinical practice.
Also on June 2, Neuronetics announced that Robert Greene was appointed Senior Vice President of Sales, effective June 1, 2026. Greene brings experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service.
Neuronetics, Inc. (NASDAQ:STIM) provides in-office treatments for patients with neurohealth disorders in the United States and internationally.
3. Empery Digital Inc. (NASDAQ:EMPD)
On July 7, 2026, Empery Digital Inc. (NASDAQ:EMPD) announced that its Board of Directors approved an amendment to the company’s stockholder rights plan to accelerate the expiration date to the close of business on July 6, 2026. The rights plan had been scheduled to expire on February 2, 2027. The Board determined that maintaining the rights plan was “no longer necessary” at this time to serve the best interests of all stockholders.
On July 1, Empery Digital provided additional information on the capital needs tied to its investment in a Midwest facility to be converted into a state-of-the-art AI data center. The company said its funding obligations are limited to the $65M required to close its 25% ownership in the private entity acquiring the facility. Under the terms of the non-binding LOI, the data center build-out costs, power usage, and operating costs will be funded solely by the potential tenant. Empery Digital said it has the capital required to fund the $65M investment from its balance sheet and does not intend to issue equity at or near current share price levels.
On June 30, Empery Digital announced that it entered into a definitive agreement for a $65M investment representing a 25% ownership stake in a private entity acquiring the Midwest facility. The facility has operated as a power-intensive industrial facility for the past three years and includes an owned substation and associated infrastructure for approximately 150 MW of currently available capacity under an existing power agreement with the local utility. A recent load study confirmed the facility’s ability to almost double available power to approximately 300 MW for AI workloads.
Empery Digital Inc. (NASDAQ:EMPD) engages in the digital asset treasury business in the United States.
2. Kalaris Therapeutics, Inc. (NASDAQ:KLRS)
On July 6, 2026, Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In connection with Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board.
David Hallal, Chairman of the Kalaris Board of Directors, said Keating brings strategic, operational, and legal expertise across multiple therapeutic areas and development stages. Hallal also thanked Jovan-Embiricos for her service over the past year, noting her role in helping Kalaris advance TH103 and evolve as a public biotech company.
On June 15, 2026, TD Cowen analyst Tara Bancroft initiated coverage of Kalaris Therapeutics with a Buy rating and no price target. Bancroft said the company’s TH103 is a “differentiated” anti-VEGF by design through more potent VEGF inhibition and retinal retention. Bancroft added that early data in wet age-related macular degeneration suggest even a single dose can achieve competitive efficacy versus the standard of care.
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) develops and commercializes treatments for prevalent retinal diseases.
1. International Flavors & Fragrances Inc. (NYSE:IFF)
On July 1, 2026, Morgan Stanley raised the firm’s price target on International Flavors & Fragrances Inc. (NYSE:IFF) to $95 from $93 and kept an Overweight rating on the shares. The firm cited adjusted estimates and higher peer multiples.
On June 30, Argus raised the firm’s price target on IFF to $85 from $80 and kept a Buy rating on the shares. Argus said that following recent underperformance, the shares are trading near the low end of their historical valuation range. The firm also said IFF’s volume growth and productivity gains can drive sustained earnings growth.
Also on June 30, IFF announced the launch of SENSORA, its advanced patent-pending pro-fragrance technology for home, fabric, and personal care applications. The company said SENSORA is designed to meet demand for a longer-lasting and more sophisticated scent experience by delivering an evolving olfactive profile with sustained release.
International Flavors & Fragrances Inc. (NYSE:IFF) manufactures and markets food, beverage, health and biosciences, scent, and complementary adjacent products in the United States and internationally.
READ NEXT: 10 Fastest Growing Asian Stocks to Buy Now and 12 High Quality Stocks to Buy for the Long Term.
Disclosure: None. Follow Insider Monkey on Google News.
